Immunotherapy with or without chemo for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy, or just one of those drugs by itself, for people with advanced colorectal cancer that has spread. It aims to see if these treatments can shrink the cancer or help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to other parts of the body (metastatic).
- Your cancer has been confirmed by a biopsy (tissue sample).
- A genetic test of your tumor shows you do not have certain mutations (KRAS, NRAS, or BRAF).
- You are generally able to care for yourself (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
This trial tests two new investigational drugs combined with either another experimental drug or an approved immunotherapy for advanced colorectal cancer that has stopped responding to standard chemotherapy. The goal is to see if these combinations can shrink tumors or slow cancer growth more effectively, and what side effects they may cause.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new medication (HLX05-N) against a standard treatment (Erbitux) for people with metastatic colorectal cancer that has not been treated before. It aims to see if the new drug works as well or better.
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
Hear when a new CRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.